Breast cancers in women with germline BRCA1/2 mutations (gBRCAm) are sensitive to platinum-based chemotherap. and PARP inhibition. Niraparib is a potent oral selective PARP inhibitor that has shown clinical benefit in patients with ovarian and prostate cancers. To assess the potential of niraparib in breast cancer, Turner and colleagues conducted a clinical trial to compare the efficacy of niraparib monotherapy compared to chemotherapy monotherapy regimens in women with advanced gBRCAm, HER2-negative breast cancer. The trial was stopped early due to futility and informative censoring in the control arm at an interim analysis and was not able to assess its primary endpoint. However, the trial's final analysis revealed an objective response rate of 35% in the niraparib arm and 31% in the control arm. Further clinical study of PARP inhibitors in women with gBRCAm breast cancer is warranted.

In preclinical studies, CD137 agonism and CSF-1R...

You do not currently have access to this content.